Insomnia medication
PreclinicalSmall molecule
Insomnia medication is one of 46 small molecule programs targeting Acute Myocardial Infarction. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
75 competitors in Acute Myocardial Infarction
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Bayer Aspirin
BayerApproved
Radicava
ShionogiApproved
Zebeta
TevaApproved
Praluent
RegeneronApproved
Eliquis
Bristol-Myers SquibbApproved
Onglyza
AstraZenecaApproved
Neoral
NovartisApproved
Nitrostat
VViatris Specialty LLC
Approved
Calan
VVal Adams
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Insomnia medication. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSamsung Medical Center